S₂-Serotonergic Receptor Inhibition (Ketanserin), Combined with Thromboxane A₂/Prostaglandin Endoperoxide Receptor Blockade (BM 13.177): Enhanced Anti-Platelet Effect

• References

• 1 Vargaftig BB, Chignard M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol 1981; 30: 263-271
• 2 Born GV R, Gorog P, Kratzer MA A. Aggregation of platelets in damaged vessels. Trans R Soc London 1981; B299: 241-250
• 3 De Clerck F, David JL, Janssen PA J. Inhibition of 5-hydroxy-tryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT₂-receptor antagonist. Agents Actions 1982; 12: 388-397
• 4 Gresele P, Arnout J, Janssens W, Deckmyn H, Lemmens J, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; 1: 991-993
• 5 Stegmeier K, Pill J, Müller-Beckman B, Schmidt FH, Witte EC, Wolff HP, Patscheke H. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and antithrombotic drug. Thromb Res 1984; 35: 379-395
• 6 De Clerck F, Somers Y, Van Gorp L. Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. Agents Actions 1984; 15: 627-635
• 7 Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT. The effects of α₂-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 1984; 55: 642-652